Last Price
0.372
Today's Change
-0.02 (5.10%)
Day's Change
0.365 - 0.396
Trading Volume
480,102
Profile
KZIA
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. John Edwin Friend II, M.D. Dr. John Edwin Friend II, M.D.
Full Time Employees: 9 9
IPO Date: 1999-01-06 1999-01-06
CIK: 0001075880 0001075880
ISIN: US48669G1058 US48669G1058
CUSIP: 48669G105 48669G105
Beta: 2.10 2.10
Last Dividend: 0.00 0.00
Dcf Diff: 0.25 0.25
Dcf: 0.12 0.12
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Address
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
12
Apps
Top Articles
1
CEO Morning Brief
2
CEO Morning Brief
US Services Activity Expands at Modest Pace for a Second Month
3
CEO Morning Brief
4
CEO Morning Brief
5
CEO Morning Brief
Ultra-rich Families Set to Control US$9.5 Tril by 2030, Says Deloitte
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
